Galectin Therapeutics (GALT) Tops Q1 EPS by 2c

Galectin Therapeutics (NASDAQ: GALT) reported Q1 EPS of ($0.19), $0.02 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Evolution Petroleum launches stock offering to fund Permian Basin deal
• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance